Indeed, the CXCL8-inhibiting effect of PLX4720 was stronger in 8305C and 8505C tumor cell lines as compared to BCPAP which would fit with the notion that not all tumors may show the same effects from a single targeted agent32. Here, CXCL8 is linked to neoplasm.